ArticleCureus2025
Hydrolyzed Protein Formula in Very-Low-Birth-Weight Infants: Predictors of Use and 20-Month Neurodevelopmental Outcome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHydrolyzed protein formulas (HPFs) are used in full-term infants to treat cow's milk protein allergy but can result in suboptimal weight gain as compared to standard infant formulas. In preterm infants, HPF may be used to promote feeding tolerance after necrotizing enterocolitis. There is limited evidence on HPF use in preterm infants after NICU discharge. The primary objective of this study was to determine predictors of HPF use at four, eight, and 20 months corrected age (CA) post-NICU discharge, and the secondary objective was to evaluate the association between HPF use at four and eight months CA and neurodevelopmental (ND) outcome (cognitive, language, and motor indices on the Bayley Scales of Infant and Toddler Development-III) at 20 months CA in very-low-birth-weight (VLBW; birth weight < 1,500 g) infants.
methodsThis was a retrospective chart review of 419 VLBW infants born in 2008-2012. Infants were categorized by diet at four and eight months into one of three groups: any maternal breast milk (MBM), HPF, and non-HPF. ND outcome was assessed with the Bayley-III. Multiple regression adjusted for the effect of risk factors on formula use and the effect of four- and eight-month diets on 20-month ND.
resultsForty-three (10.3%), 45 (10.7%), and 350 (83.5%) infants at four months and 22 (5.5%), 41 (10.3%), and 297 (74.4%) infants at eight months were on a diet of MBM, HPF, and non-HPF, respectively. HPF use was predicted by multiple gestation (odds ratio (OR) 3.01 (95% CI 1.57-5.99)) and stage 2-3 necrotizing enterocolitis (OR 2.54 (95% CI 1.09-5.94)) at four and eight months, respectively. In multiple regression, infants on non-HPF at eight months had worse language/receptive language scores than the other two groups.
conclusionsIn our retrospective analysis of VLBW infants, we did not observe any statistically significant difference in 20-month ND outcomes among infants who received HPF as compared to those who received non-HPF or MBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.